The variant of the SARS-CoV-2 virus known as B.1.1.7 is still susceptible to antibodies induced after COVID-19 infection or immunization with a currently available vaccine, according to Emory University...

A team of researchers based in Stockholm, Sweden, has demonstrated that individuals exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have antibodies for the disease up to nine...

As new variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to emerge, fueling the continued spread of the coronavirus disease 2019 (COVID-19) pandemic, a new study offers...

Researchers in the United States say the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant – P.1 – that has recently emerged in Brazil shows a worrying level of resistance...

Ask Eric Weaver about pandemics, and he's quick to remind you of a fact that illustrates the fleeting nature of human memory and the proximal nature of human attention: The first pandemic of the...

New York has the first case of a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant called B.1.526, picked up by genomic surveillance research from Columbia University. The findings...

In a major advance in the treatment of multiple myeloma, a CAR T-cell therapy has generated deep, sustained remissions in patients who had relapsed from several previous therapies, an international clinical...

Researchers in the United States and Canada have conducted a study showing that just a single dose of either the Pfizer-BioNTech or Moderna vaccine against severe acute respiratory syndrome coronavirus...

NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. MABTHERA IV NHL AND CLL 160310 For the treatment of Non-Hodgkin’s Lymphoma and Chronic Lymphocytic...

NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. VAQTA® Hepatitis A vaccine, Inactivated (hepatitis A virus, inactivated) Consumer Medicine Information What...